5.50MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Can Fite Biopharma Ltd
Currency: USD Updated: 2026-02-06 Key Insights
Can Fite Biopharma Ltd's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 111 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 70.00.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Can Fite Biopharma Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Can Fite Biopharma Ltd Highlights
StrengthsRisks
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06 The current financial score of Can Fite Biopharma Ltd is 5.51, ranking 156 out of 159 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 155.00K, representing a year-over-year decrease of 21.32%, while its net profit experienced a year-over-year decrease of 45.28%.
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Key Metrics
Total revenue
Operating profit
Total assets
SG&A
Relevant data have not been disclosed by the company yet.
Key Metrics
Cash flow from operating activities
Income after tax
Relevant data have not been disclosed by the company yet.
Key Metrics
Cash flow from operating activities
Total revenue
Relevant data have not been disclosed by the company yet.
Key Metrics
Relevant data have not been disclosed by the company yet.
Can Fite Biopharma Ltd's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of Can Fite Biopharma Ltd is 7.35, ranking 79 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -0.00, which is -269275.00% below the recent high of 4.31 and -38002412.50% above the recent low of -608.04.
Valuation Dimensions
Industry Ranking 111/159
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of Can Fite Biopharma Ltd is 7.00, ranking 118 out of 159 in the Pharmaceuticals industry. The average price target is 4.50, with a high of 11.00 and a low of 2.50.
Support & Resistance
Relevant data have not been disclosed by the company yet.
Strong Buy
Buy
Hold
Sell
Strong Sell
Can Fite Biopharma Ltd
CANF
2
Vertex Pharmaceuticals Inc
VRTX
33
Financial Forecasting
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of Can Fite Biopharma Ltd is 7.01, ranking 86 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 4.58 and the support level at 3.80, making it suitable for range-bound swing trading.
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Institutional Confidence
Currency: USD Updated: 2026-02-06Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Rhumbline Advisers Ltd. Partnership
Abalone Asset Management Ltd.
UBS Financial Services, Inc.
BNP Paribas Securities Corp. North America
CAPTRUST Financial Advisors
Two Sigma Investments, LP
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Can Fite Biopharma Ltd. The Pharmaceuticals industry's average is 5.18. The company's beta value is 1.03. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Beta vs S&P 500 index
1.03
240-Day Maximum Drawdown
+85.54%
240-Day Volatility
+324.74%
Volatility
Downside Risk-Adjusted Return
Maximum Daily Upside Volatility
Maximum Daily Downside Volatility
Can Fite Biopharma Ltd
CANF
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
